Median Technologies' eyonis Lung Cancer Screening Gets CE Marking in Europe

Median Technologies (ALMDT.PA) said Friday its AI-based software-as-a-medical-device eyonis LCS secured CE marking under the new European Medical Device Regulation. The approval allows commercialization of the technology in the European Union for use in screening programs to detect and diagnose lung cancer. The US Food and Drug Administration approved Eyonis LCS in February, the cancer diagnosis-focused artificial intelligence company added.